Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.2350 (2.5%) ($9.2350 - $9.2350) on Mon. Feb. 7, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.2% (three month average) | RSI | 48 | Latest Price | $9.2350(2.5%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.3% a day on average for past five trading days. | Weekly Trend | FOLD declines -1.2% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(64%) IWO(53%) IWM(50%) IWC(49%) XBI(48%) | Factors Impacting FOLD price | FOLD will decline at least -2.1% in a week (0% probabilities). VIXM(-29%) VXX(-13%) UUP(-11%) UNG(-9%) EDOC(-5%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.1% (StdDev 4.2%) | Hourly BBV | 1.1 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $0.19(-97.94%) | Resistance Level | $9.37 | 5 Day Moving Average | $9.12(1.26%) | 10 Day Moving Average | $9.14(1.04%) | 20 Day Moving Average | $9.37(-1.44%) | To recent high | -25.9% | To recent low | 6.5% | Market Cap | $2.385b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |